A Comparison of the Treatment of Pressure Ulcers in Spinal Cord Injury Subjects With HP011—101 Ointment to That of Treatment With the Sites Usual Standard Care
This study has been terminated.
Sponsor:
Healthpoint
Information provided by (Responsible Party):
Healthpoint
ClinicalTrials.gov Identifier:
NCT01433159
First received: September 12, 2011
Last updated: February 12, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The trial will compare the effects of 14 days treatment with HP011 101 versus Standard Care in subjects with Stage I or II pressure ulcers as a complication of spinal cord injury, measured as change from baseline in composite wound bed scores of the PUSH 3.0 tool.
| Condition | Intervention | Phase |
|---|---|---|
|
Pressure Ulcers Spinal Cord Injury |
Drug: HP011-101 (Xenaderm Ointment) Drug: Standard Care |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Comparison of HP011-101 to Standard Care in the Management of Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury |
Resource links provided by NLM:
Further study details as provided by Healthpoint:
Primary Outcome Measures:
- Change from baseline in composite PUSH score [ Time Frame: baseline, 14 Days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Adverse Event [ Time Frame: 21 Days ] [ Designated as safety issue: Yes ]
| Enrollment: | 19 |
| Study Start Date: | September 2011 |
| Study Completion Date: | January 2013 |
| Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: HP011-101 |
Drug: HP011-101 (Xenaderm Ointment)
The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
|
|
Active Comparator: Various
Standard Care at each site other than Xenaderm Ointment or other BCT2-containing products
|
Drug: Standard Care
No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
|
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Provide informed consent, or assent if less than 18 years of age.
- Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
- Have pressure ulcers ≤ Stage II severity, ≥ 2 cm² and ≤ 100 cm² in aggregate area (each area will be measured, including ulcer area (cm2), perimeter (cm) and greatest depth (cm) using the ARANZ Silhouette™ wound imaging and measurement device, and will remain at the treating facility for at least three weeks.
- In the opinion of the Investigator, are maintaining an adequate nutritional status and are receiving a full caloric diet, either orally or by tube.
- All female subjects must have a negative urinary pregnancy test at screening.
Have, within 12 weeks prior to screening, clinical laboratory test results indicating:
- Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels < 3x upper limit of the Healthpoint normal range
- HbA1C ≤ 12%
- Hemoglobin ≥ 8 g/dL
- Serum albumin, pre-albumin, and serum total protein measurements must be collected or obtained. These will serve as baseline covariates for analysis, but will not be used as inclusion criteria.
The most recently obtained laboratory values must be evaluated against the stated criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
- For ulcers that will require surgical debridement, any debridement modality may be used at baseline, but the ulcer must remain a Stage I or Stage II partial thickness wound after debridement.
- Have spinal cord injuries, which are motor complete or motor incomplete injuries that are based on American Spinal Injury Association (ASIA) Impairment classifications A, B, C, and D.
Exclusion Criteria:
- Have a spinal cord injury from, epidural abscess, infection, neurodegenerative process, or malignancy.
- Have a known hypersensitivity to any of the test articles or their components.
- Have received therapy with another investigational agent within thirty (30) days of screening.
- Are pregnant or nursing.
- Have received systemic treatment with glucocorticoids for > 10 consecutive days within 1 week prior to the start of the study.
- Have received chemotherapy or radiation therapy within the past 5 years.
- Have clinical evidence of bacterial or fungal infection of the any open wound per visual/clinical assessment.
- Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
- Have had documented osteomyelitis in the ulcer area within 6 months prior to screening.
- Have end-stage renal disease, are receiving treatment for cancer (except for non-melanoma skin cancer within the past five years), or untreated peripheral vascular disease.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01433159
Locations
| United States, California | |
| VA Medical Center, Long Beach | |
| Long Beach, California, United States, 90822 | |
| Santa Clara Valley Medical Center | |
| San Jose, California, United States, 95128 | |
| United States, Florida | |
| James A. Haley Veterans Hospital, Tampa | |
| Tampa, Florida, United States, 33612 | |
| United States, New Jersey | |
| Kessler Institute for Rehabilitation | |
| West Orange, New Jersey, United States, 07052 | |
| United States, North Carolina | |
| Carolinas Research | |
| Charlotte, North Carolina, United States, 28203 | |
Sponsors and Collaborators
Healthpoint
Investigators
| Study Chair: | Herbert B Slade, MD | Healthpoint |
More Information
No publications provided
| Responsible Party: | Healthpoint |
| ClinicalTrials.gov Identifier: | NCT01433159 History of Changes |
| Other Study ID Numbers: | 011-101-09-043 |
| Study First Received: | September 12, 2011 |
| Last Updated: | February 12, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Healthpoint:
|
Pressure Ulcers Spinal Cord Injury Healthpoint Xenaderm 011-101 |
Additional relevant MeSH terms:
|
Pressure Ulcer Spinal Cord Injuries Ulcer Skin Ulcer Skin Diseases Spinal Cord Diseases |
Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds and Injuries Pathologic Processes |
ClinicalTrials.gov processed this record on May 22, 2013